Gastro Treatment Company RedHill Announces Successful Clinical Trial in Treatment of H. Pylori Infection
RedHill’s new pill managed to eradicate 84% of H. pylori bacteria, as opposed to 58% in patients receiving the standard of care
Nasdaq and Tel Aviv-listed pharmaceutical company RedHill Biopharma Ltd. announced Monday it has received positive results for its antibiotic treatment of Helicobacter pylori gastric infections, the company announced Monday. In a stage 3 study conducted by the company, RedHill’s new pill TALICIA, which combines the antibiotics rifabutin and amoxicillin, managed to eradicate 84% of H. pylori bacteria, as opposed to 58% in patients receiving the standard of care. H. pylori is a type of gastric bacteria, linked with increased risks of developing ulcers and cancer.
Founded in 2009, Tel Aviv-headquartered RedHill develops orally-administered medicine for gastrointestinal and inflammatory diseases. RedHill is traded at a market capitalization of $207 million, as of market close Monday.
Redhill pills. Photo: PR